No Data
Takeda Pharmaceutical: Navigating Patent Expiration With a Strong Pipeline and Anticipated Growth
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Maintains Target Price $20
TD Cowen analyst Michael Nedelcovych maintains $Takeda Pharmaceutical(TAK.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 54
Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement With Takeda to Discover Molecular Glue Degraders
Collaboration will leverage Degron's GlueXplorer platform to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation Degron will receive upfront paym
6-K: Report of foreign private issuer (related to financial reporting)
Takeda Canada Inc. Concludes Letter of Intent (LOI) With the Pan-Canadian Pharmaceutical Alliance (PCPA) for LIVTENCITY (Maribavir) for the Treatment of Adults With a Post-Transplant Cytomegalovirus (CMV) Infection
Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) for LIVTENCITY (maribavir) for
Express News | Takeda's dengue vaccine is pre-qualified by WHO